|
|
|
LifeScienceHistory.com - Check us out on Instagram
Virginia Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing VirginiaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
AmpliPhi BioSciences Corporation
| | | Phone: | (800) 985-3730 | Year Established: | 1989 | Employees: | 6 | Ticker: | APHB | Exchange: | NYSE | Main Contact: | Paul C. Grint, M.D., CEO | | Other Contacts: | Igor P. Bilinsky, Ph.D., COO Alexander Gaidamaka, Ph.D., VP, Chemistry, Manufacturing & Control Steve Martin, CFO Sandra Morales, Ph.D., VP, Research
| | Company Description | AmpliPhi Biosciences (formerly Targeted Genetics) is a biotechnology company dedicated to the development of innovative antibacterial solutions to improve human and animal health through the application of its proprietary bacteriophage platform.
AmpliPhi was the first company worldwide to demonstrate the clinical efficacy of bacteriophage technology in a controlled, human clinical trial. It has invested over 15 years into developing phagebased therapies with its lead product BioPhagePA, a
topical treatment for otitis, a chronic inner ear infection, poised to enter Phase III clinical trials in humans. BioPhagePR, a systemic treatment for lung infections in cystic fibrosis patients in late preclinical development and a pipeline of other potential
products, including in veterinary medicine and personal hygiene. | |
|
|
|
|
|